The Matilda Centre for Research in Mental Health and Substance Use, The University of Sydney, Sydney, NSW, Australia.
Addiction and Mental Health Group (AIM), University of Bath, Bath, UK.
Addiction. 2022 Feb;117(2):284-298. doi: 10.1111/add.15581. Epub 2021 Jul 15.
The idea that cannabis is a 'gateway drug' to more harmful substances such as opioids is highly controversial, yet has substantially impacted policy, education and how we conceptualize substance use. Given a rise in access to cannabis products and opioid-related harm, the current study aimed to conduct the first systematic review and meta-analysis on the likelihood of transitioning from cannabis use to subsequent first-time opioid use, opioid use disorders (OUD), dependence or abuse.
Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, pubMed/MEDLINE, Scopus, EMBASE, PsychINFO, Cochrane Central Register of Controlled Trials and Informit Health Collection were searched for full-text articles assessing the likelihood of transitioning from cannabis to subsequent opioid use, and from opioid use to OUD, abuse or dependence given prior cannabis use. Analysis of subpopulations within studies were discussed narratively, and E-values were calculated to assess the potential influence of unmeasured confounding.
Six studies provided relevant data from the United States, Australia and New Zealand between 1977 and 2017, a total sample of 102 461 participants. Random-effects analysis of the adjusted pooled effect size indicates that the likelihood of transitioning from cannabis to opioid use, relative to non-cannabis users, is odds ratio (OR) = 2.76, 95% confidence interval (CI) = 2.26-3.36, whereas the likelihood of transitioning from opioid use to OUD, abuse or dependence given prior cannabis use is OR = 2.52, 95% CI = 1.65-3.84. While the evidence was determined to be of low quality with moderate risk of bias, E-values suggest that these findings are robust against unmeasured confounding.
A systematic review and meta-analysis found that while people who use cannabis are disproportionately more likely to initiate opioid use and engage in problematic patterns of use than people who do not use cannabis, the low quality of the evidence must be considered when interpreting these findings.
大麻是“入门毒品”,会使人更容易接触到更危险的物质,如阿片类药物,这种观点极具争议性,但它对政策、教育以及我们对物质使用的概念产生了重大影响。鉴于大麻制品的获取途径增加以及阿片类药物相关危害的增加,本研究旨在对从大麻使用转为首次使用阿片类药物、阿片类药物使用障碍(OUD)、依赖或滥用的可能性进行首次系统评价和荟萃分析。
根据系统评价和荟萃分析首选报告项目(PRISMA)指南,检索了 PubMed/MEDLINE、Scopus、EMBASE、PsychINFO、Cochrane 对照试验中心注册库和 Informit 健康收藏,以获取评估从大麻转为随后使用阿片类药物、以及从阿片类药物使用转为 OUD、滥用或依赖的可能性的全文文章,前提是曾使用过大麻。对研究中的亚人群进行了叙述性分析,并计算了 E 值以评估未测量混杂因素的潜在影响。
六篇研究报告了 1977 年至 2017 年间来自美国、澳大利亚和新西兰的相关数据,共有 102461 名参与者。对调整后合并效应大小的随机效应分析表明,与非大麻使用者相比,从大麻转为阿片类药物使用的可能性,优势比(OR)为 2.76,95%置信区间(CI)为 2.26-3.36,而在曾使用过大麻的情况下,从阿片类药物使用转为 OUD、滥用或依赖的可能性,OR 为 2.52,95%CI 为 1.65-3.84。虽然证据质量被确定为低质量,存在中度偏倚风险,但 E 值表明,这些发现对未测量的混杂因素具有稳健性。
系统评价和荟萃分析发现,虽然使用大麻的人比不使用大麻的人更有可能开始使用阿片类药物,并出现问题性使用模式,但在解释这些发现时必须考虑证据质量低的问题。